Phosphorylated Alpha-Synuclein Skin Biopsy Diagnostic Algorithm
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for synucleinopathies, such as Parkinson's disease and multiple system atrophy, have low accuracy and are not easily accessible, leading to misdiagnosis and inadequate patient care, as they rely on clinical criteria and do not provide a reliable biomarker for alpha-synuclein outside the central nervous system.
Innovation Solution
A system and method for identifying alpha-synuclein deposition in skin biopsies using a multifaceted algorithm that combines clinical features with phosphorylated alpha-synuclein distribution patterns and nerve fiber densities to accurately differentiate between multiple system atrophy and Parkinson's disease, offering a diagnostic biomarker with high specificity and sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If clinical criteria are used for diagnosis, then the diagnostic method is simple and accessible, but the diagnostic accuracy is low (less than 80%)
Solution Approach 1:
The patent introduces phosphorylated alpha-synuclein as an intermediary biomarker that bridges clinical symptoms and definitive diagnosis. This biomarker can be detected in peripheral tissues through skin biopsy, serving as a mediator that provides accurate diagnostic information without requiring direct examination of central nervous system tissue, thus maintaining accessibility while improving accuracy
Solution Approach 2:
The patent extracts the diagnostic information from the central nervous system by detecting phosphorylated alpha-synuclein in peripheral tissues (skin biopsy). This extraction allows diagnosis to be performed outside the CNS, making the diagnostic method more accessible while maintaining high accuracy through specific biomarker detection
2Measurement precision
If phosphorylated alpha-synuclein detection in skin biopsy is implemented, then the diagnostic accuracy is significantly improved, but the device complexity and procedure complexity increase
Solution Approach 1:
The patent extracts the diagnostic target (phosphorylated alpha-synuclein) from the central nervous system to peripheral tissues (skin). This extraction simplifies the overall diagnostic approach by using easily accessible tissue samples while maintaining diagnostic accuracy, as the biomarker is present in peripheral tissues without requiring complex CNS access procedures
Solution Approach 2:
The patent uses skin biopsy as a surrogate copy or model for assessing central nervous system pathology. The phosphorylated alpha-synuclein detected in peripheral skin tissue serves as a representative copy of the pathological process occurring in the CNS, allowing accurate diagnosis without directly examining the complex CNS structures
3Measurement precision
If phosphorylated alpha-synuclein detection in skin biopsy is implemented, then the diagnostic accuracy is significantly improved, but the difficulty of detecting and measuring increases
Solution Approach 1:
The patent uses phosphorylated alpha-synuclein as an intermediary biomarker that is detectable in peripheral tissues. This intermediary serves as a measurable proxy for CNS pathology, making the detection process more feasible while maintaining high diagnostic accuracy through specific immunohistochemical or biochemical assays
Data Source
AI summary
Various embodiments provide a synuclein signature for distinguishing multiple system atrophy (MSA) from Parkinson's disease (PD) in a patient, the synuclein signature comprises a quantitation of total P-SYN across a posterior cervical biopsy site, a distal thigh biopsy site, and a distal leg biopsy site, and a distribution coefficient of P-SYN across the posterior cervical biopsy site, the distal thigh biopsy site, and the distal leg biopsy site.